Prellis Biologics hires new CEO, raises $35M towards 3D bioprinted lymph node R&D 

Prellis Biologics has raised $35 million and appointed a new CEO as it seeks to advance the development of its proprietary 3D bioprinted lymph node.  Raised via a Series C funding round led by Celesta Capital and Avidity Partners, and backed by Khosla Ventures, SOSV, True Ventures and Lucas Venture Group, the cash will be […]